Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹254Cr
Rev Gr TTM
Revenue Growth TTM
51.02%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

NURECA
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -48.3 | -16.8 | -14.8 | -19.5 | -20.1 | -4.5 | -0.5 | 18.3 | 87.0 | 68.6 | 21.0 | 49.8 |
| 25 | 24 | 30 | 27 | 21 | 23 | 34 | 30 | 31 | 35 | 34 | 36 |
Operating Profit Operating ProfitCr |
| -16.3 | -13.7 | 4.4 | -19.0 | -26.1 | -11.6 | -7.6 | -15.2 | 3.8 | -1.6 | 8.7 | 8.2 |
Other Income Other IncomeCr | 2 | 3 | 3 | 6 | -1 | 6 | 3 | 1 | 2 | 3 | 2 | 2 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Depreciation DepreciationCr | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| -2 | -1 | 4 | 1 | -6 | 3 | 0 | -3 | 2 | 1 | 5 | 5 |
| 0 | 0 | 1 | 1 | -2 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
|
Growth YoY PAT Growth YoY% | -9.3 | 82.8 | 200.0 | -43.3 | -171.2 | 333.8 | -116.6 | -1,747.1 | 159.5 | -51.2 | 856.3 | 233.2 |
| -7.2 | -3.3 | 9.2 | 0.8 | -24.4 | 8.2 | -1.5 | -10.6 | 7.8 | 2.4 | 9.6 | 9.4 |
| -1.5 | -0.7 | 2.9 | 0.2 | -4.2 | 1.7 | -0.5 | -2.8 | 2.5 | 0.8 | 3.6 | 3.9 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 60.6 | 114.7 | 19.7 | -56.4 | -17.4 | 19.3 | 30.7 |
| 53 | 90 | 152 | 200 | 126 | 102 | 117 | 136 |
Operating Profit Operating ProfitCr |
| 14.6 | 9.8 | 28.8 | 21.7 | -13.5 | -11.1 | -6.9 | 5.0 |
Other Income Other IncomeCr | 0 | 0 | 3 | 8 | 7 | 11 | 12 | 9 |
Interest Expense Interest ExpenseCr | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 2 |
Depreciation DepreciationCr | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| 9 | 9 | 62 | 61 | -11 | -3 | 1 | 13 |
| 3 | 2 | 16 | 16 | -2 | -1 | 1 | 2 |
|
| | 2.7 | 625.2 | -3.0 | -118.3 | 78.3 | 147.2 | 1,157.7 |
| 10.1 | 6.4 | 21.7 | 17.6 | -7.4 | -1.9 | 0.8 | 7.4 |
| 8.9 | 9.1 | 62.0 | 45.0 | -8.3 | -1.8 | 0.8 | 10.8 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 0 | 0 | 10 | 10 | 10 | 10 | 10 | 10 |
| 8 | 15 | 153 | 193 | 185 | 183 | 184 | 189 |
Current Liabilities Current LiabilitiesCr | 15 | 10 | 19 | 12 | 9 | 9 | 12 | 24 |
Non Current Liabilities Non Current LiabilitiesCr | 0 | 9 | 4 | 4 | 3 | 3 | 3 | 2 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 23 | 33 | 181 | 206 | 187 | 193 | 190 | 193 |
Non Current Assets Non Current AssetsCr | 1 | 1 | 5 | 13 | 20 | 13 | 20 | 32 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 0 | -8 | 35 | 1 | 10 | -3 | -19 |
Investing Cash Flow Investing Cash FlowCr | 0 | 0 | -110 | -3 | -16 | 18 | 8 |
Financing Cash Flow Financing Cash FlowCr | 0 | 8 | 92 | -7 | -2 | -1 | 0 |
|
Free Cash Flow Free Cash FlowCr | 0 | -8 | 34 | -2 | 10 | -4 | -21 |
| 4.9 | -123.9 | 75.2 | 3.1 | -124.0 | 151.2 | -2,255.7 |
CFO To EBITDA CFO To EBITDA% | 3.4 | -81.7 | 56.7 | 2.5 | -68.1 | 26.6 | 253.1 |
| Financial Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 602 | 1,362 | 300 | 255 | 210 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 13.0 | 30.3 | 0.0 | 0.0 | 247.5 |
Price To Sales Price To Sales | 0.0 | 0.0 | 2.8 | 5.3 | 2.7 | 2.8 | 1.9 |
Price To Book Price To Book | 0.0 | 0.0 | 3.7 | 6.7 | 1.5 | 1.3 | 1.1 |
| 0.0 | 1.0 | 7.8 | 23.1 | -15.5 | -20.8 | -22.4 |
Profitability Ratios Profitability Ratios |
| 35.1 | 35.0 | 53.4 | 48.1 | 32.1 | 34.1 | 38.0 |
| 14.6 | 9.8 | 28.8 | 21.7 | -13.5 | -11.1 | -6.9 |
| 10.1 | 6.4 | 21.7 | 17.6 | -7.4 | -1.9 | 0.8 |
| 110.7 | 38.5 | 38.4 | 29.7 | -5.2 | -1.1 | 1.3 |
| 78.4 | 42.8 | 28.4 | 22.1 | -4.2 | -0.9 | 0.4 |
| 26.5 | 18.9 | 25.0 | 20.5 | -4.0 | -0.9 | 0.4 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Nureca Ltd (NSE-listed) is a digital-first, debt-free healthcare and wellness company headquartered in India, operating under a scalable, asset-light business model. The company specializes in technology-enabled home healthcare, wellness, and medical devices, with a strategic shift from a product-centric to a service-driven, integrated **connected healthcare ecosystem**. Nureca’s primary brand is **Dr Trust**, complemented by **Dr Physio** (focused on pain management and mobility) and **Trumom** (mother and baby care).
With over **1.34 crore products sold globally** and a strong digital presence across e-commerce and direct-to-consumer (D2C) platforms, Nureca has established itself as a trusted name in preventive and self-driven healthcare in India.
---
### **Business Model & Revenue Streams**
- **Digital-First D2C Focus**: Over **93% of revenue (as of Oct 2025)** comes from online sales, primarily through:
- E-commerce platforms (Amazon, Flipkart)
- Own website: drtrust.in
- Online pharmacy partners (e.g., 1mg)
- **Quick Commerce Expansion**: Strategic partnerships with Blinkit, Swiggy Instamart, and Zepto enable **sub-30-minute delivery** in urban markets. Quick commerce is projected to contribute **15% of revenue by FY26**.
- **Offline Growth**: The company has expanded to **23 out of 28 Indian states**, with **192+ active distributors**, a **52+ member sales team**, and presence in **22,000+ retail touchpoints** as of Q1 FY25.
- **Emerging Channels**: Exports (currently <0.02% of turnover), corporate sales, and OEM manufacturing are being developed as new growth vectors.
---
### **Product Portfolio & Innovation**
Nureca offers **102+ active SKUs** across five key categories:
1. **Chronic Disease Monitoring**
- Digital BP monitors (e.g., BP iCheck Pro, Wrist Monitor), glucometers, pulse oximeters, ECG devices
- Each of BP monitors, nebulizers, and self-monitoring blood glucose (SmBG) devices holds ~20% share in India’s chronic care device market.
2. **Mother & Baby Care (Trumom Brand)**
- Breast pumps, sterilizers, baby scales, fetal dopplers
- Niche innovations: *Mustard Seed Baby Head Shaping Pillow*, *Junior Compressor Nebulizer (pediatric)*
3. **Orthopedic & Pain Management (Dr Physio)**
- TENS massagers, heat/cold therapy packs, heat belts, electric massagers (e.g., *Supervolt Octacore*), cervical/coccyx pillows
4. **Wellness & Lifestyle**
- Smart scales (e.g., *8 Electrode Smart Scale*, *Legend Smart Scale*), thermometers (*InstaScan*, *Pet Thermometer*), sleep and travel aids (*Cloudwalker pillow*, *Yawnicorn Cuddle Pillow*)
5. **Nutrition & Supplements**
- Glutathione, biotin, fish oil, *Jointrack®* (joint health), *Dr Trust Red Yeast* (heart health)
**Recent Launches (FY25):**
- Rechargeable Scalp Massager with Red Light Therapy
- Pregnancy Support Pillow
- Non-Contact Infrared Pet Thermometer
- EpsoMAX (natural pain-relief body wash & foot cream)
---
### **Manufacturing & Supply Chain**
- **Nureca Technologies Pvt Ltd (NTPL)**: Wholly owned, USFDA-registered (Reg. No. 3036779619) manufacturing subsidiary, operational since **April 2022** in Mohali, Punjab.
- **Capabilities**:
- Currently produces 32% of units in-house, reducing forex risk and lead times.
- ISO 9001:2015 & ISO 13485:2016 certified.
- 13 CDSCO approvals; 7 products with **USFDA 510(k)-exempt status**.
- Products: BP monitors, nebulizers, thermometers, massagers, heating pads, breast pumps, stethoscopes.
- **New Facility in Sundran, Punjab**:
- 2.25-acre site under development, delayed due to statutory approvals.
- Target capacity: **200,000–400,000 units/month**.
- Will produce glucometers, strips, wheelchairs, orthopedic soft goods, and OEM devices.
- **Integrated Ecosystem**: Leverages exclusive ancillary suppliers and mold vendors; achieves **45-day average manufacturing lead time**.
---
### **Connected Health Platform: Dr Trust 360**
A cornerstone of Nureca’s strategic evolution, **Dr Trust 360** is a **freemium AI-powered connected health app** with **1.6 million active users (Aug 2025, +24% YoY)**.
#### **Key Features**
- **Free Tier**:
- Blood pressure, heart rate, weight tracking
- Historical trend analysis, smart reports
- Smart OCR (Smart Sensei™) to digitize readings from non-connected devices
- **Pro Subscription (Paid)**:
- AI-generated personalized diet plans based on Dr Trust device data
- Calorie & water intake tracking
- HbA1c estimation
- Family/caregiver alerts via WhatsApp
- Advanced health reports and behavioral nudges
#### **Integration & Use Cases**
- Syncs with IoT-enabled devices: BP monitors, glucometers, smart scales, ECG, and wearable biosensors.
- Enables **remote patient monitoring**, real-time alerts, and virtual doctor consultations.
- Data shared via WhatsApp/email for caregivers and physicians.
---
### **Digital & Data-Centric Strategy**
- **D2C Platform Investments**: Enhanced UI/UX, mobile apps (iOS/Android), influencer marketing, and customer service.
- **Data-Driven Innovation**:
- Informs product design, pricing, and feature optimization
- Enables **personalized marketing, demand forecasting, and inventory management**
- **Supply Chain Excellence**: Digitization has improved responsiveness, reduced lead times, optimized working capital, and lowered carrying costs.
- **Marketing**: Uses AI and analytics for targeted campaigns, conversion improvement, and trend forecasting.
---
### **Competitive Advantage (Business Moat)**
Nureca’s moat rests on the **synergy of Product, Placement, and Promotion**, supported by:
- **Product**: 102+ SKUs, 102 design patents, USFDA & CE approvals
- **Placement**: Pan-India reach via 192+ distributors, 22,000+ retail outlets, 1mg, and quick commerce
- **Promotion**: Strong digital branding, over **131,000 positive online reviews**, high customer satisfaction
- **Technology**: AI, IoT integration, and first-party data leverage
- **Brand Equity**: **DrTrust** is a **"Well-Known Trademark"** in India
---
### **Strategic Pillars (as of Oct 2025)**
1. **Pan-India Sales Network Expansion**: Target expansion into all 28 states and top 500 cities.
2. **Manufacturing & Capacity Scaling**: Onboarding new facility in Punjab; targeting domestic and OEM/export markets.
3. **Connected Health Leadership**: Expand **Dr Trust 360** into a **one-stop virtual healthcare platform** with preventive and pre-diagnostic focus.
---
### **Financial & Operational Strengths**
- **Debt-Free Balance Sheet**: No long-term borrowings; healthy liquidity.
- **Asset-Light Model**: Capital efficient, high scalability.
- **High Operating Leverage**: 67% ROCE in FY21; continued margin improvement targeted via AI-driven cost optimization.
---
### **Key Milestones & Recent Developments**
- **Oct 2025**: Dr Trust 360 app hits 1.6M users; 93% revenue from online channels
- **May 2025**: New Punjab facility approved; entry into contract manufacturing with pharma players
- **Aug 2025**: Quick commerce drives incremental demand; offline presence at 10,000+ counters
- **Jan 2025**: Cloudwalker pillow launch; roadmap to scale to 500+ cities
- **Jun 2024**: Achieved "phygital" presence in 23 states; 1M+ D2C customers
- **May 2022**: IPO listing on NSE/BSE; Dr Trust 360 platform launched
- **Founded in 2016**, listed in **2021**, now serving over **1.34 crore customers** globally
---